O'Keefe Kenneth W 4
4 · Jazz Pharmaceuticals plc · Filed Nov 9, 2020
Insider Transaction Report
Form 4
O'Keefe Kenneth W
Director
Transactions
- Sale
Ordinary Shares
2020-11-05$156.44/sh−4,513$706,003→ 18,667 total - Sale
Ordinary Shares
2020-11-05$152.57/sh−2,001$305,295→ 27,666 total - Sale
Ordinary Shares
2020-11-05$153.74/sh−2,740$421,255→ 24,926 total - Sale
Ordinary Shares
2020-11-05$155.14/sh−1,746$270,867→ 23,180 total
Holdings
- 4,445(indirect: By Trust)
Ordinary Shares
Footnotes (6)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.319 to $152.83 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.355 to $154.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F4]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $154.91 to $155.73 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F5]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $156.00 to $156.99 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F6]Shares are held for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary.